The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Open accessAbstract
BACKGROUND: Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. METHODS: A total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 microg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily placebo, or 3 million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks. RESULTS: A significantly higher proportion of patients who received peginterferon alfa-2a plus ribavirin had a sustained virologic response (defined as the absence of detectable HCV RNA 24 weeks after cessation of therapy) than of patients who received interferon alfa-2b plus ribavirin (56 percent vs. 44 percent, P<0.001) or peginterferon alfa-2a alone (56 percent vs. 29 percent, P<0.001). The proportions of patients with HCV genotype 1 who had sustained virologic responses were 46 percent, 36 percent, and 21 percent, respectively, for the three regimens. Among patients with HCV genotype 1 and high base-line levels of HCV RNA, the proportions of those with sustained virologic responses were 41 percent, 33 percent, and 13 percent, respectively. The overall safety profiles of the three treatment regimens were similar; the incidence of influenza-like symptoms and depression was lower in the groups receiving peginterferon alfa-2a than in the group receiving interferon alfa-2b plus ribavirin. CONCLUSIONS: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Self-citationMcHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Self-citationPoynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
On closed testing procedures with special reference to ordered analysis of variance
MARCUS, R., ERIC, P., & GABRIEL, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,423
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Self-citationPeginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
Heathcote, E. J., Shiffman, M. L., Cooksley, W. G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432302 · Cited by 874
Self-citationEASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999
(1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80154-8 · Cited by 700
Lindsay, K. L., Trepo, C., Heintges, T., Shiffman, M. L., Gordon, S. C., Hoefs, J. C., Schiff, E. R., Goodman, Z. D., Laughlin, M., Yao, R., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.26371 · Cited by 668
Self-citation
Cited by
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Self-citationEASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Self-citationTelaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Self-citationProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,826
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
Self-citationLai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
Self-citationLevey, A. S., Atkins, R., Coresh, J., Cohen, E. P., Collins, A. J., Eckardt, K.-U., Nahas, M. E., Jaber, B. L., Jadoul, M., Levin, A., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002343 · Cited by 1,516
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040842 · Cited by 1,233
Self-citationPeginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
McHutchison, J. G., Lawitz, E. J., Shiffman, M. L., Muir, A. J., Galler, G. W., McCone, J., Nyberg, L. M., Lee, W. M., Ghalib, R. H., Schiff, E. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808010 · Cited by 1,190
Self-citationJanssen, H. L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U. S., Cakaloglu, Y., Simon, C., So, T. M., Gerken, G., de Man, R. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17701-0 · Cited by 1,162
EASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
Self-citationRauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T., Bochud, M., Battegay, M., Bernasconi, E., Borovicka, J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.056 · Cited by 1,137
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Self-citationTelaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., & Muir, A. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806104 · Cited by 1,089
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.023 · Cited by 1,088
Course and outcome of hepatitis C
Hoofnagle, J. H. (2002) · Hepatology · doi:10.1002/hep.1840360704 · Cited by 1,084
Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011) · Hepatology · doi:10.1002/hep.24641 · Cited by 1,076
Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
Arora, S., Thornton, K., Murata, G., Deming, P., Kalishman, S., Dion, D., Parish, B., Burke, T., Pak, W., Dunkelberg, J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009370 · Cited by 1,076
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.-P., Bourlière, M., Gharakhanian, S., Bengtsson, L., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807650 · Cited by 1,025
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
Feld, J. J., & Hoofnagle, J. H. (2005) · Nature · doi:10.1038/nature04082 · Cited by 992
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
AASLD practice guidelines: Evaluation of the patient for liver transplantation†
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 939
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
Sumpter, R., Loo, Y.-M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S. M., & Gale, M. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2689-2699.2005 · Cited by 898
Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., Foschi, F. G., Lenzi, M., Mazzella, G., Verucchi, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.015 · Cited by 897
Davis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
Chung, R. T., Andersen, J., Volberding, P., Robbins, G. K., Liu, T., Sherman, K. E., Peters, M. G., Koziel, M. J., Bhan, A. K., Alston, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032653 · Cited by 875
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
Mangia, A., Santoro, R., Minerva, N., Ricci, G. L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042608 · Cited by 840
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819
Poynard, T., Yuen, M.-F., Ratzin, V., & Lai, C. L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15109-4 · Cited by 809
Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease
Foy, E., Li, K., Wang, C., Sumpter, R., Ikeda, M., Lemon, S. M., & Gale, M. (2003) · Science · doi:10.1126/science.1082604 · Cited by 788
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Sherman, K. E., Flamm, S. L., Afdhal, N. H., Nelson, D. R., Sulkowski, M. S., Everson, G. T., Fried, M. W., Adler, M., Reesink, H. W., Martin, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014463 · Cited by 750
Self-citationRomero-Gómez, M., Del Mar Viloria, M., Andrade, R. J., Salmerón, J., Diago, M., Fernández-Rodríguez, C. M., Corpas, R., Cruz, M., Grande, L., Vázquez, L., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.049 · Cited by 732
Self-citationSide effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1053/jhep.2002.36810 · Cited by 727
Self-citationThompson, A. J., Muir, A. J., Sulkowski, M. S., Ge, D., Fellay, J., Shianna, K. V., Urban, T., Afdhal, N. H., Jacobson, I. M., Esteban, R., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.013 · Cited by 723
Self-citationKwo, P. Y., Lawitz, E. J., McCone, J., Schiff, E. R., Vierling, J. M., Pound, D., Davis, M. N., Galati, J. S., Gordon, S. C., Ravendhran, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60934-8 · Cited by 704
Antiviral agents active against influenza A viruses
De Clercq, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2175 · Cited by 668
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Treating viral hepatitis C: efficacy, side effects, and complications
Manns, M. P., Wedemeyer, H., & Cornberg, M. (2006) · Gut · doi:10.1136/gut.2005.076646 · Cited by 659
Targeting RNA with Small Molecules
Thomas, J. R., & Hergenrother, P. J. (2008) · Chemical Reviews · doi:10.1021/cr0681546 · Cited by 647
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 643
Interferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Thrombocytopenia associated with chronic liver disease
Afdhal, N., McHutchison, J., Brown, R., Jacobson, I., Manns, M., Poordad, F., Weksler, B., & Esteban, R. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.03.009 · Cited by 583
Projecting future complications of chronic hepatitis C in the United States
Davis, G. L., Albright, J. E., Cook, S. F., & Rosenberg, D. M. (2003) · Liver Transplantation · doi:10.1053/jlts.2003.50073 · Cited by 576
Focus on hepatocellular carcinoma
Bruix, J., Boix, L., Sala, M., & Llovet, J. M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00058-3 · Cited by 570
Side effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1002/hep.1840360730 · Cited by 556
Self-citationMuir, A. J., Bornstein, J. D., & Killenberg, P. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032502 · Cited by 541
Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection
Adams, L. A., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., Kench, J., Farrell, G., McCaughan, G. W., & Jeffrey, G. P. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.048389 · Cited by 539
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Zeuzem, S., Jacobson, I. M., Baykal, T., Marinho, R. T., Poordad, F., Bourlière, M., Sulkowski, M. S., Wedemeyer, H., Tam, E., Desmond, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401561 · Cited by 517
Ramos-Casals, M., Stone, J. H., Cid, M. C., & Bosch, X. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60242-0 · Cited by 513
Ferenci, P., Fried, M. W., Shiffman, M. L., Smith, C. I., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.04.009 · Cited by 512
Self-citationManns, M. P., Buti, M., Gane, E., Pawlotsky, J.-M., Razavi, H., Terrault, N., & Younossi, Z. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.6 · Cited by 506
Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
Shiffman, M. L., Suter, F., Bacon, B. R., Nelson, D., Harley, H., Solá, R., Shafran, S. D., Barange, K., Lin, A., Soman, A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066403 · Cited by 493
Self-citationRosen, H. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1006613 · Cited by 487
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Peginterferon and Ribavirin for Chronic Hepatitis C
Hoofnagle, J. H., & Seeff, L. B. (2006) · New England Journal of Medicine · doi:10.1056/nejmct061675 · Cited by 476
Conjeevaram, H. S., Fried, M. W., Jeffers, L. J., Terrault, N. A., Wiley–Lucas, T. E., Afdhal, N., Brown, R. S., Belle, S. H., Hoofnagle, J. H., Kleiner, D. E., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.06.008 · Cited by 472
Self-citationProlonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
Di Bisceglie, A. M., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Everhart, J. E., Wright, E. C., Lee, W. M., Lok, A. S., Bonkovsky, H. L., Morgan, T. R., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707615 · Cited by 465
Self-citationShiffman, M. L., Di Bisceglie, A. M., Lindsay, K. L., Morishima, C., Wright, E. C., Everson, G. T., Lok, A. S., Morgan, T. R., Bonkovsky, H. L., & Lee, W. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.014 · Cited by 453
Self-citationZEUZEM, S. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.02.007 · Cited by 448
Webster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
Alberti, A., & Benvegnù, L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00008-4 · Cited by 438
Jacobson, I. M., Dore, G. J., Foster, G. R., Fried, M. W., Radu, M., Rafalsky, V. V., Moroz, L., Craxi, A., Peeters, M., Lenz, O., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60494-3 · Cited by 437
Self-citationThe design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
Korenaga, M., Wang, T., Li, Y., Showalter, L. A., Chan, T., Sun, J., & Weinman, S. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506412200 · Cited by 428
Hepatitis C in the HIV-Infected Person
Sulkowski, M. S., & Thomas, D. L. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00012 · Cited by 405
Reesink, H. W., Zeuzem, S., Weegink, C. J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L., Purdy, S., Kauffman, R., Alam, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.013 · Cited by 401
Honda, M., Sakai, A., Yamashita, T., Nakamoto, Y., Mizukoshi, E., Sakai, Y., Yamashita, T., Nakamura, M., Shirasaki, T., Horimoto, K., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.049 · Cited by 400
Laguno, M., Murillas, J., Blanco, J. L., Martínez, E., Miquel, R., Sánchez-Tapias, J. M., Bargallo, X., García-Criado, A., Lazzari, E. D., Larrousse, M., et al. (2004) · AIDS · doi:10.1097/00002030-200409030-00003 · Cited by 387
Perni, R. B., Almquist, S. J., Byrn, R. A., Chandorkar, G., Chaturvedi, P. R., Courtney, L. F., Decker, C. J., Dinehart, K., Gates, C. A., Harbeson, S. L., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.899-909.2006 · Cited by 386
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Manns, M., Marcellin, P., Poordad, F., de Araujo, E. S. A., Buti, M., Horsmans, Y., Janczewska, E., Villamil, F., Scott, J., Peeters, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60538-9 · Cited by 376
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
Dixit, N. M., Layden-Almer, J. E., Layden, T. J., & Perelson, A. S. (2004) · Nature · doi:10.1038/nature03153 · Cited by 369
Sugimoto, K., Ikeda, F., Stadanlick, J., Nunes, F. A., Alter, H. J., & Chang, K.-M. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.026 · Cited by 369
Mazzaferro, V., Romito, R., Schiavo, M., Mariani, L., Camerini, T., Bhoori, S., Capussotti, L., Calise, F., Pellicci, R., Belli, G., et al. (2006) · Hepatology · doi:10.1002/hep.21415 · Cited by 367
Hepatitis C and renal disease: an update
Meyers, C. M., Seeff, L. B., Stehman-Breen, C. O., & Hoofnagle, J. H. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00828-x · Cited by 365
Andreone, P., Colombo, M. G., Enejosa, J. V., Koksal, I., Ferenci, P., Maieron, A., Müllhaupt, B., Horsmans, Y., Weiland, O., Reesink, H. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.045 · Cited by 365
Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19
Khalili, J. S., Zhu, H., Mak, N. S. A., Yan, Y., & Zhu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25798 · Cited by 359
Bräu, N., Salvatore, M., Ríos-Bedoya, C. F., Fernández-Carbia, A., Paronetto, F., Rodríguez-Orengo, J. F., & Rodríguez-Torres, M. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.07.006 · Cited by 359
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy†
Everson, G. T., Trotter, J., Forman, L., Kugelmas, M., Halprin, A., Fey, B., & Ray, C. (2005) · Hepatology · doi:10.1002/hep.20793 · Cited by 357
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Rong, L., Dahari, H., Ribeiro, R. M., & Perelson, A. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000544 · Cited by 355
Soriano, V., Puoti, M., Sulkowski, M., Cargnel, A., Benhamou, Y., Peters, M., Mauss, S., Bräu, N., Hatzakis, A., Pol, S., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3281084e4d · Cited by 349
Doyle, S. E., Schreckhise, H., Khuu‐Duong, K., Henderson, K., Rosler, R., Storey, H., Yao, L., Liu, H., Barahmand‐pour, F., Sivakumar, P., et al. (2006) · Hepatology · doi:10.1002/hep.21312 · Cited by 348
Berenguer, M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.05.002 · Cited by 342
Applications of gold nanoparticles in virus detection
Draz, M. S., & Shafiee, H. (2018) · Theranostics · doi:10.7150/thno.23856 · Cited by 342
Metadata
- Authors
- Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., & Yu, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-09-26
- Volume
- 347
- Issue
- 13
- Pages
- 975-982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2027545702
- Cited by
- 6,389
- References
- 19
- FWCI
- 201.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.